Indeed, the proteoforms derived from the alternative splicing of p53 and p63 possess different seroreactivity and for some specific proteoforms a higher diagnostic ability than the canonical proteins, suggesting that more than one proteoform of each member of the p53 family should be included in diagnostic platforms for the blood-based diagnosis of CRC patients. The gene discussed is TP53; the disease is colorectal carcinoma.